RhoA在小鼠胚胎围着床期子宫内膜的表达及其意义

目的探讨RhoA在小鼠胚胎植入过程中的表达及其生物学作用。方法取胚胎围种植期（D0至D6天）昆明小鼠子宫作切片，用免疫组织化学方法和图像分析方法对RhoA在子宫内膜中的表达进行定位和半定量分析。结果RhoA主要分布于小鼠子宫内膜腺上皮、腔上皮和基质细胞。受精后，RhoA在子宫内膜的含量高于未孕组（P＜0．05）；受精后第4d（植入期），小鼠子宫内膜腔上皮中RhoA的含量明显增多，明显高于未孕及植入前各时间组（P＜0．05），并逐渐向基质细胞延伸，第5d广泛分布在蜕膜细胞和基质细胞，到第6天大部分子宫内膜基质区域及腺上皮的细胞中有大量的RhoA分布。RhoA在小鼠子宫内膜组织中的表达强度在受精后呈逐渐上升趋势。结论①RhoA可能参与了胚胎的种植和子宫内膜容受性的建立；②还可能间接参与植入后胚胎的滋养层扩展、分化及子宫内膜蜕膜化反应。     

胰岛素、胰岛素样生长因子Ⅰ及其受体在PCOS患者子宫内膜的表达

目的探讨胰岛素及其受体、胰岛素样生长因子I及其受体在多囊卵巢综合征患者子宫内膜的表达特点。方法利用免疫组化实验技术分析INS、INS-R、IGF-I和IGF-IR在多囊卵巢综合征和非多囊卵巢综合征不孕症患者子宫内膜中的表达情况,对结果进行图像分析,并利用SPSS10.0软件进行统计学分析,比较各组间的差异。结果1.多囊卵巢综合征患者子宫内膜IGF-I和INS-R表达水平明显高于对照组,差异有显著性(P<0.01)。其中多囊卵巢综合征中子宫内膜增生症患者的IGF-I和INS-R表达水平高于多囊卵巢综合征组增殖期患者,差异有显著性(P<0.05)。2.IGF-IR和INS在多囊卵巢综合征患者与对照组子宫内膜的表达水平无明显差异(P>0.05)。结论多囊卵巢综合征患者子宫内膜异常增生可能与局部IGF-I和INS-R表达异常有关。     

胰岛素通过PI3K/AKT/GSK3通路促多囊卵巢综合征患者子宫内膜病变机制的研究

目的 研究多囊卵巢综合征(PCOS)胰岛素抵抗(IR)与非抵抗患者子宫内膜的PI3 K/AKT/GSK3信号通路蛋白表达情况;探讨胰岛素在PCOS患者子宫内膜病变的作用机制.方法 以2006年3月至2010年5月北京天坛医院妇产科门诊治疗的34例PCOS患者为实验组,以同期因输卵管因素不孕行诊刮术的非PCOS患者30例为对照组.实验组患者行OGTT、INS实验及性腺6项测定,根据是否存在IR将PCOS患者分为Ⅰ组(IR组)和Ⅱ组(非IR组).对实验组和对照组患者子宫内膜石蜡标本应用免疫组化方法测定PI3K(磷脂酰肌醇-3激酶)、p-AKT(PPKB,磷酸化蛋白激酶B)、GSK3(糖原合成酶激3)的表达.结果 PCOS患者的PDK表达水平要明显高于对照组(P=0.000,0.003),其中PCOS Ⅰ组最高(P=0.022).在p-AKT表达上,PCOS患者要明显高于对照组(P=0.011,0.000),其中以PCOS Ⅰ组最高(P =0.002),而在GSK3表达上,PCOS Ⅰ组,Ⅱ组和对照组三组之间差异无统计学意义(P＞0.05).结论胰岛素信号通路PI3K、p-AKT可能是IR PCOS患者子宫内膜病变的信号转导通路.     

丁苯酞对脑缺血再灌注大鼠HSP70及TLR4的影响研究

目的：研究丁苯酞预处理对脑缺血再灌注大鼠细胞凋亡及HSP70及TLR4表达的影响。方法：将144只实验大鼠随机分成：假手术组（ Sham组）、缺血再灌注组（ IR组）、给予NBP干预的缺血再灌注组（ NBP组）各48只,各组再根据缺血2 h后再灌注的时间6 h、12 h、24 h和48 h分为4个小组,每小组各12只。通过Longa改良线栓法制备大鼠缺血再灌注模型,NBP组待大鼠缺血再灌注模型建立后立即予NBP灌胃,IR及Sham组作为对照组,予等量的生理盐水灌胃。比较不同组大鼠神经功能缺损评分、细胞凋亡数、HSP70及TLR4表达的差异。结果：再灌注时间为12 h、24 h和48 h时,NBP组的神经功能缺损评分均低于IR组（P均＜0.05）;在任意灌注时间段内,IR、NBP组的凋亡细胞数均显著高于Sham组（P均＜0.01）,NBP组的细胞凋亡数均显著低于IR组（P均＜0.01）;在任意灌注时间段内,NBP、IR组的HSP70和TLR4阳性细胞数均显著高于Sham组（ P均＜0.01）;与IR组相比, NBP组的HSP70和TLR4的表达量显著降低（ P均＜0.01）。结论：NBP可以通过抑制HSP70和TLR4的表达量,改善细胞的凋亡数和机体炎症反应,从而起到保护神经功能的作用。     

淫羊藿苷通过HIF-1α/VEGF通路介导的血管生成调节大鼠种植窗期子宫内膜容受性

目的 探究淫羊藿苷通过缺氧诱导因子-1α(HIF-1α)/血管内皮生长因子（VEGF）通路介导的血管生成调节大鼠种植窗期子宫内膜容受性的机制。方法 取SD雌性大鼠通过灌胃羟基脲+肾上腺素皮下注射的方法建立子宫内膜容受障碍模型，随机分为模型组、淫羊藿苷低剂量（10 mg/kg）组、淫羊藿苷高剂量（20 mg/kg）组、淫羊藿苷高剂量（20 mg/kg）+空载组、淫羊藿苷高剂量（20 mg/kg）+HIF-1α敲低组，每组20只，另选20只SD雌性大鼠灌胃+皮下注射等剂量生理盐水做对照组，将各组雌鼠与雄鼠合笼得到孕鼠并分组处理后，测定各组大鼠性激素[雌激素（E2）、孕酮激素（P）]水平、平均着床胚胎数；免疫组织化学染色检测各组大鼠子宫内膜微血管密度（MVD）；扫描电子显微镜检测各组大鼠子宫内膜超微结构；免疫组织化学染色和免疫印迹检测各组大鼠子宫内膜组织HIF-1α/VEGF通路蛋白表达。结果 与对照组相比，模型组大鼠子宫内膜表面附着大量短细微绒毛，未发现胞饮突，血清E2与P水平、平均着床胚胎数、子宫内膜MVD、HIF-1α与VEGF蛋白表达明显降低（P<0.05）；与模型组相比，淫羊...     

生存素在子宫内膜异位症中的表达特点

目的 探讨生存素在子宫内膜异位症病灶及在位内膜中的表达情况及相关因素。方法 采用免疫组化抗生物素蛋白-过氧化物酶染色法（SP法）检测38例2002年12月至2004年9月在我院妇科住院的未经治疗的子宫内膜异位症患者的异位及在位内膜标本中生存素的表达，以同期因子宫肌瘤或宫颈病变接受手术的生育期妇女的子宫内膜作为对照。结果 病例组异位内膜与在位内膜均有生存素的表达并且缺乏周期性变化（P〉0．05），异位内膜腺上皮生存素表达的强度高于在位内膜（P〈0．05）。结论 子宫内膜异位症的异住及在位内膜均表达生存素，而且在位内膜间质及异住内膜腺上皮表达也缺乏周期性。     

子宫腺肌症雌激素受体、孕激素受体与bcl-2的表达

目的 探讨雌激素受体（ER）、孕激素受体（PR）和bcl-2在子宫腺肌症中异位和在位内膜的表达及意义。方法 用免疫组化EnVision法检测40例子宫腺肌症在位子宫内膜和肌间异位内膜ER、PR和bcl-2的表达情况。结果 在位和异位子宫内膜组织中均有ER、PR和bcl-2的阳性表达。其中腺上皮阳性表达率高于间质（P〈0．05），且异位内膜的腺上皮bcl-2阳性表达率高于在位组织（P〈0．05）；ER和PR的表达两者差异无显著性（P〉0．05）。异位内膜腺体ER、PR与bcl-2表达具有相关性（P〈0．01）。结论 子宫腺肌症异位和在位子宫内膜组织中均有ER、PR和bcl-2的阳性表达，可能与子宫腺肌症的发生、发展有关。     

卵巢子宫内膜异位症患者miR-200c和ZEB1基因表达及其临床意义

目的 探讨卵巢子宫内膜异位症（EMs）患者微小RNA(miR)-200c和E盒结合锌指蛋白1(ZEB1)基因表达及其临床意义。方法 收集2022年1月至2022年6月在石家庄市人民医院手术治疗的卵巢EMs患者异位、在位内膜组织各50例；选取同期由于宫颈上皮内瘤样病变（CIN）Ⅲ行全子宫切除术患者的子宫内膜组织50例作为对照组。采用实时荧光定量PCR法测定miR-200c和ZEB1基因表达；采用免疫组化法测定ZEB1蛋白表达。比较各组miR-200c和ZEB1相对表达量；比较各组ZEB1蛋白阳性率；分析miR-200c与ZEB1相关性；分析miR-200c和ZEB1与卵巢EMs关系。结果 异位内膜组miR-200c和ZEB1相对表达量高于在位内膜组和对照组（P<0.05）；在位内膜组miR-200c和ZEB1相对表达量高于对照组（P<0.05）。异位内膜组ZEB1蛋白阳性率高于在位内膜组和对照组（P<0.05）；在位内膜组ZEB1蛋白阳性率高于对照组（P<0.05）。经Pearson分析显示，miR-200c与ZEB1呈线性正相关（P<0.05）。经多因素L...     

无生长追赶SGA幼鼠生长激素和胰岛素受体后信号交联对话的研究

目的：在生长激素（GH）和胰岛素（INS）共享受体后PI3K通路基础上探讨无生长追赶的出生低体重（NCU-SGA）幼鼠GH和INS抵抗的受体后机制，以及2者受体后信号通路的交联对话（cross-talk）。方法:取4周龄NCU-SGA雄性大鼠，采用Western印记及免疫共沉淀技术分别测定NCU-SGA幼鼠在基础状态下、胰岛素激发以及先给予GH受体后信号通路JAK2阻滞剂AG490后再行胰岛素激发后（AG490+INS组）肝组织胰岛素受体底物-1（IRS-1）及其下游信号磷酸化Akt(p-Akt)的表达。结果:（1）IRS-1信号表达： SGA鼠基础状态、INS激发后和AG490+INS组，3组间的IRS-1总蛋白及IRS-1磷酸化水平与正常对照组（C组）无显著差异（P＞0.05）。（2）p-Akt信号表达： C组基础状态时无p-Akt信号表达，INS刺激后表达明显增强。SGA鼠基础状态时p-Akt已有显著表达（慢性激活），INS刺激后表达较基础状态增加，但增殖显著低于正常对照组（P＜0.01）；AG490+INS组的p-Akt较JAK2未被阻断时明显增强（P＜0.01），但仍显著低于正常对照组（P＜0.01)，提示GH的信号干扰了INS受体后IRS-1至Akt的信号转导。结论:NCU-SGA幼鼠INS抵抗的发生与IRS-1-Akt通路受损有关，GH抵抗经GH和INS 2者受体后信号通路间的交联对话（cross-talk）使IRS-1至Akt间的信号转导解偶联,诱导和加重了INS抵抗；而PI3K-Akt可能是发生该解偶联的主要交汇点。     

辛伐他汀降低脂质肾损害大鼠肾组织中骨调素表达

目的 观察高脂血症肾损害大鼠肾组织中骨调素（OPN）和单核细胞趋化蛋白1 （MCP-1）表达变化及辛伐他汀对其表达的影响。方法 将雄性wistar大鼠随机分为对照组，高脂组，辛伐他汀治疗组，每组10只。观察12周。实验监测尿蛋白量、血脂、肾功能及肾组织病理学改变；免疫组化技术检测肾组织MCP-1表达，用RT-PCR、免疫印迹检测OPN mRNA和蛋白表达。 结果 实验结束时，高脂模型组及辛伐他汀组血清TC、TG、LDL-C、24h尿蛋白显著高于对照组（P＜0.01）；辛伐他汀组血清TC、TG、LDL-C、24h尿蛋白明显低于高脂组（P＜0.01），而 HDL-C则明显高于高脂组（P＜0.01）；高脂组大鼠肾小球系膜细胞增生，系膜区增宽，小管间质炎性细胞浸润，而辛伐他汀组病理改变较高脂组有所减轻；高脂组和辛伐他汀组大鼠肾组织中MCP-1、OPN mRNA和蛋白表达显著上调（P＜0.01）；而辛伐他汀组大鼠肾组织中上述指标的表达较高脂组有明显下调（P＜0.05）；肾组织中OPN蛋白表达与其MCP-1表达和尿蛋白量呈高度正相关。结论 辛伐他汀可能通过降低大鼠肾组织中OPN和MCP-1的表达，从而减轻小管间质巨噬细胞浸润，从而降低了高脂血症肾损害。     

多囊卵巢综合征胰岛素抵抗患者Gly972Arg多态性与子宫内膜胰岛素受体底物1表达的关系

目的:研究多囊卵巢综合征(Polycystic ovary syndrome,PCOS)胰岛素抵抗(Insulin resistance,IR)患者胰岛素受体底物1(Insulin receptor substrate,IRS-1)基因Gly972Arg多态性与子宫内膜IRS-1表达的关系。方法:PCOS患者51例,用聚合酶链反应(PCR)技术,检测IRS-1Gly972Arg多态性。于月经周期第1天刮取子宫内膜,合并胰岛素抵抗者28例,非胰岛素抵抗者23例,应用免疫组化技术检测子宫内膜IRS-1,计算机图像分析系统分析子宫内膜IRS-1的表达。结果:Gly972Arg多态性:51例PCOS患者中,基因型GG 49例,基因型GA 2例,IR组与无IR组各1例,两组比较无统计学意义。子宫内膜IRS-1的表达:IR组、非IR组IRS-1表达的灰度值分别为131.94±18.39、78.16±6.87,比较有统计学意义(P<0.01)。结论:IRS-1Gly972Arg的突变率较低,其多态性在PCOS IR组与无IR组比较无统计学意义(P>0.05),不影响子宫内膜IRS-1的表达。     

控制血糖促进糖尿病大鼠心肌葡萄糖代谢

目的 观察控制血糖对2型糖尿病大鼠心肌能量代谢的影响.方法 18只SD雄性大鼠随机分为对照组(6只)、糖尿病组(6只)和治疗组(6只).采用高脂喂养及腹腔注射链脲佐菌素建立2型糖尿病大鼠模型,应用离体心脏Langendorf灌注,测定心肌葡萄糖氧化率;采用Western blot法检测心肌细胞GLUT4的表达.结果 糖尿病组大鼠心肌葡萄糖总氧化量较对照组减少(P相似文献   

饮食因素对大鼠脂肪细胞葡萄糖转运蛋白4的影响

目的:研究饮食因素对大鼠脂肪细胞葡萄糖转运蛋白4(GLUT4)的影响。方法:实验大鼠随机分为正常组(n=10)、模型组(n=10)和饮食干预组(n=10)。正常组以基础饲料喂养10周;模型组以高糖高脂饲料喂养10周;饮食干预组以高糖高脂饲料喂养4周后,改喂基础饲料6周。Westernblot法检测各组大鼠脂肪细胞内、外膜GLUT4含量。结果:模型组大鼠脂肪细胞内、外膜GLUT4含量均低于正常组(P<0.05)。与模型组大鼠相比,饮食干预组大鼠脂肪细胞内膜GLUT4含量无显著差异,但细胞外膜GLUT4含量增加P<0.05)。结论:高糖高脂饮食可能通过降低脂肪细胞GLUT4含量及其转位使大鼠产生胰岛素抵抗。饮食干预可提高脂肪细胞GLUT4含量并改善其转位,增加葡萄糖的摄取,提高胰岛素敏感性。     

Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome

BACKGROUND: Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages. The aim of the present study was to evaluate the uterine effects of metformin in patients with PCOS who ovulated under metformin. METHODS: Thirty-seven non-obese primary infertile anovulatory patients with PCOS and another 30 age- and body mass index-matched healthy women (control group) were studied. PCOS patients were treated with metformin (850 mg twice daily) for 6 months, whereas the control group did not receive any treatment. In these PCOS patients who ovulated whilst under metformin treatment (PCOS group) and in controls, uterine, sub-endometrial and endometrial blood flow, and endometrial thickness and pattern were evaluated using serial ultrasonographic assessments. RESULTS: Before treatment, uterine, sub-endometrial and endometrial blood flows were significantly lower in patients with PCOS than in the control group. All indexes of uterine vascularization were significantly improved in the PCOS group with metformin treatment and were not different from the controls. Nor was any difference in endometrial thickness and pattern detected between PCOS and control groups. After grouping the data of PCOS patients who ovulated under metformin for cycles with favourable/unfavourable reproductive outcome, no difference in any parameter was observed. CONCLUSIONS: Metformin improves all surrogate markers of endometrial receptivity in PCOS patients, without difference between patients who had favourable or unfavourable reproductive outcome.     

Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide

Aim: To investigate the expression of silent information regulator 1 (SIRT1) in rats with polycystic ovary syndrome (PCOS) and its alteration after exenatide treatment. Methods: PCOS rat model was established by dehydroepiandrosterone induction. The animals were randomly divided into exenatide treatment group (EX group, n = 10), metformin treatment group (MF group, n = 10), PCOS group (PCOS group, n = 9) and normal control group (NC group, n = 10). Histological changes of the ovarian tissues were examined by HE staining. SIRT1 expression in the ovarian tissue was detected by RT-PCR and immunohistochemistry. Results: Rats in the PCOS group lost their estrous cycle. Histological observation of the ovary showed saccular dilatation of the follicle, decreased number of corpora lutea, fewer layers of granulosa cells aligned loosely, and thickened layer of theca cells. The changes in reproductive hormones and the development of insulin resistance suggested the successful establishment of the animal models. Immunohistochemistry and Q-PCR detected the mRNA and protein expressions of SIRT1 in the ovary tissues of rats in the normal control group. The SIRT1 expression was significantly lower in PCOS group than in control group (P < 0.05); after drug intervention, the SIRT1 expression significantly increased in EX and MF groups (compared with the PCOS group), whereas no significant difference was noted between the EX group and MF group. Conclusions: The SIRT1 expression in the ovary tissue decreases in PCOS rats (compare with the normal rats) but can be up-regulated after Ex or MF treatment. These drugs may affect the process and development of PCOS by regulating the SIRT1 expression. Exenatide may be therapeutic for PCOS by up-regulating the SITR1 expression.     

GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma.

Glucose is provided to cells by a family of glucose transport facilitators known as GLUTs. These transporters are expressed in a tissue specific manner and are overexpressed in many primary tumors of these tissues. Regulation of glucose transport facilitator expression has been demonstrated in endometrial tissue and endometrial adenocarcinoma. The following experiments were conducted to quantify and localize the expression of GLUT1 and GLUT8 in benign endometrium and compare this expression to endometrial cancer. Endometrial tissue samples were obtained from random hysterectomy specimens of patients with benign indications for surgery and endometrial cancer. Immunoblot and immunolocatization studies were performed using GLUT1 and GLUT8 specific antisera. Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant). A 44 and a 35.4 kDa immunoreacive species was demonstrated in endometrium and endometrial cancer for GLUT1 and GLUT8, respectively. Upregulation of GLUT1 expression was demonstrated with increasing grade of tumors (P<0.002). GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium (P<0.001). Apical localization by GLUT1 and GLUT8 was demonstrated in endometrial glands. GLUT1 and GLUT8 demonstrated diffuse intracellular localization in the cancer subtypes. GLUT1 and GLUT8 are expressed in both human endometrium and endometrial cancer. There appears to be a step-wise progression in GLUT1 and GLUT8 expression as tumor histopathology worsens. GLUT1 and GLUT8 may be important markers in tumor differentiation, as well as providing energy to rapidly dividing tumor cells.     

抑制核因子κB与妊娠糖尿病大鼠子宫胰岛素抵抗的关系

目的:观察妊娠糖尿病(GDM)大鼠子宫组织中,核因子-κB(NF-κB)及葡萄糖转运蛋白-4(GLUT-4)的表达,探讨GDM子宫胰岛素抵抗与抑制NF-κB表达的关系。方法:将30只SD孕鼠随机分为正常妊娠对照(NC)组、妊娠糖尿病(GDM)组和PDTC干预组,每组10只。采用链脲霉素(STZ)腹腔注射建立大鼠GDM模型。PDTC干预组大鼠在建模后每日腹腔注射PDTC(40 mg/kg)。大鼠分娩前及妊娠20 d处死留取子宫标本,观察子宫组织的病理变化。用免疫组化染色法及Western blot法检测子宫组织中GLUT-4与NF-κB的表达变化。结果:GDM组NF-κB的表达明显高于NC组(P0.01);PDTC干预组NF-κB的表达明显降低(P0.01)。GDM组GLUT-4的表达明显低于NC组(P0.01);PDTC干预组GLUT-4的表达与GDM组比较明显升高(P0.01)。结论:抑制核因子κB的活性能使GDM大鼠子宫组织中GLUT-4的表达升高,提示GDM大鼠子宫胰岛素抵抗的发生可能与核因子κB活化介导的GLUT-4表达下调有关。     

Ezh2、Runx3和caspase-3在子宫内膜样腺癌中的表达及相关性

目的 探讨Ezh2、Runx3和caspase-3在正常子宫内膜、子宫内膜增殖症和子宫内膜样腺癌组织中的表达及相关性.方法 采用组织芯片技术和免疫组织化学SP法检测30例正常子宫内膜组织、30例单纯性增生内膜、30例复杂伴不典型增生内膜、72例子宫内膜样腺癌组织中Ezh2、Runx3和caspase-3蛋白的表达.结果 Ezh2、Runx3和caspase-3蛋白在子宫内膜样腺癌组织中的阳性表达率分别为83.3%(60/72)、26.4%(19/72)、33.3%(24/72);Ezh2在腺癌组织中的阳性率明显高于正常和各型增生内膜(16.7%、33.3%、63.3%;P<0.05),Runx3在腺癌组织中的阳性率明显低于正常和单纯性增生内膜(80.0%、56.7%;P<0.01),caspase-3在腺癌组织中的阳性率明显低于正常和各型增生内膜(86.7%、73.3%、63.3%;P<0.01),差异均有统计学意义.Ezh2和Runx3的阳性表达与组织分级、临床分期和肌层浸润深度均有关(均P<0.05),与淋巴结转移均无关(P>0.05);caspase-3的阳性表达与组织分级有关(P<0.05),而与临床分期、浸润深度及淋巴结转移均无关(P>0.05).Ezh2与Runx3的蛋白表达呈负相关(rs=-0.262,P<0.05).结论 Ezh2、Runx3和caspase-3可能在子宫内膜样腺癌的发生发展过程中发挥重要作用,联合检测其表达可为子宫内膜样腺癌的预后监测及新基因靶点的探寻提供依据.

Abstract：

Objective To investigate the role of the expression of Ezh2, Runx3 and caspase-3 proteins and their correlation in the pathogenesis of endometrial carcinoma. Methods Expression of Ezh2, Runx3 and caspase-3 proteins was examined by tissue microarray technique and immunohistochemistry (SP method) in 72 cases of endometrial adenocarcinomas, 60 endometrial hyperplasia and 30 normal endometrial tissues. Results The positive expression rates of Ezh2, Runx3 and caspase-3 proteins in endometrial adenocarcinomas were 83.3%(60/72), 26.4%(19/72) and 33.3%(24/72), respectively. The positive rate of Ezh2 protein in endometrial carcinomas was higher than that in normal endometrium and endometrial hyperplasia(16.7%, 33.3%, 63.3%;P<0.05). However, the positive rate of Runx3 in endometrial carcinomas was lower than that in normal endometrium and endometrial hyperplasia(80.0%,56.7%; P<0.01). The positive rate of caspase-3 protein in endometrial carcinomas was lower than that in normal endometrium and endometrial hyperplasia(86.7%, 73.3%, 63.3%;P<0.01). Positive expression of Ezh2 and Runx3 was related to the histological grade, FIGO stage, and depth of invasion of endometrial adenocarcinomas(P<0.05), but it was not related to the lymph node metastasis (P>0.05). Positive expression of caspase-3 protein was related to the histological grade(P<0.05), but it was not related to the FIGO stage, depth of invasion and the lymph node metastasis of endometrial adenocarcinomas (P>0.05). The expression of Ezh2 protein was negatively correlated to that of Runx3 (rs=-0.262, P<0.05). Conclusions Abnormal expression of Ezh2, Runx3 and caspase-3 proteins is associated with the development and progression of endometrioid adenocarcinoma. Combined analysis of Ezh2, Runx3 and caspase-3 may offer prognostic information for patients with endometrial cancer.     

阿托伐他汀对自发性高血压大鼠细胞色素P450羟化酶基因表达的影响

目的： 评价阿托伐他汀对自发性高血压大鼠（SHR）血压和细胞色素P450羟化酶(CYP)4A1的调节作用。方法： 18只SHR随机分为3组：SHR对照组、阿托伐他汀50 mg组(HATV组)和10 mg组(LATV组)；6只Wistar-Kyoto大鼠(WKY)作为正常对照组。给药共10周,分别于给药前和给药后每2周测量大鼠尾动脉收缩压(SBP)；RT-PCR、Western blotting法检测心、肝、肾及主动脉中CYP4A1 mRNA和蛋白质表达；并测定血脂含量。结果： 用药前SHR各组SBP均显著高于WKY组(P<0.01)；HATV组在给药后第6、8、10周和LATV组在给药后第10周SBP明显低于SHR对照组(P<0.05或P<0.01)。在CYP4A1 mRNA及其蛋白质表达中，SHR对照组4种组织均明显高于WKY组(P<0.01或P<0.05)；给药10周后，HATV组心、肾及主动脉和LATV组肾和主动脉的表达均明显低于SHR对照组(P<0.01或P<0.05)；同时，用药2组血脂水平亦明显低于SHR对照组(P<0.01或 P<0.05)。结论： 阿托伐他汀可下调CYP4A1基因的表达，这可能是其降低血压的作用机制之一。     

高胰岛素增加早孕小鼠子宫内膜蜕膜化进程中血管紧张素Ⅱ的表达

目的探讨高水平胰岛素对早孕小鼠子宫内膜蜕膜化进程中血管标志分子血管紧张素Ⅱ(Ang-Ⅱ)的影响。方法皮下注射胰岛素构建高水平胰岛素动物模型。将其与正常雄鼠交配后收集妊娠第6、7和8天(D6、D7和D8)的子宫组织及血清,并监测血糖。另将其与输精管结扎的雄鼠交配构建人工诱导蜕膜化模型,于假孕D8收集子宫组织。ELISA检测血清中胰岛素及雌、孕激素的变化,real-time PCR检测子宫内膜Ang-ⅡmRNA的表达,Western blot对子宫内膜Ang-Ⅱ蛋白表达进行检测。结果高胰岛素模型中血清胰岛素水平于妊娠D6、D7和D8均明显升高(P0.001)、雌激素水平于妊娠D8出现显著下降(P0.05),孕激素水平于妊娠D6、D8出现明显下降(P0.01)。与对照组比较,高胰岛素模型中子宫内膜组织中Ang-Ⅱ的mRNA及蛋白的表达显著增加(P0.05)。结论高胰岛素增加孕鼠蜕膜化进程中子宫内膜组织Ang-Ⅱ的表达,从而影响子宫内膜蜕膜化进程中的血管生成。